Conference abstractPublished 18 Aug 2016
Canakinumab: a promising monoclonal antibody in the treatment of cardiovascular diseases
Universidad de Cartagena, Colombia.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Canakinumab is a totally human monoclonal antibody anti-IL-1β developed by Novartis, whose mode of action is based on the neutralization of IL-1β signaling, which leads to suppression of inflammation in patients with autoimmune disorders. The IL-1β acts as a mediator of the peripheral immune response during infection and inflammation. By the antigen-antibody binding, canakinumab inhibits the action of IL1-β avoiding its pro-inflammatory effects. Currently, it is being evaluated as a new possible agent directed against IL-1β, with the goal of reducing the rate of cardiovascular events and new onset diabetes.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectCardiology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Fernando Gabriel Manzur Jattin”
